GlassScriptPhysician profile
Michael W Montesi
NPI 1194816652
$1,458.09
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $149 · 2021: $393.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $318.04 | 2019-2021 | |
| Mylan Specialty L.P. | $165.21 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $145.09 | 2019-2020 | |
| Amgen INC. | $142.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $126.63 | 2019-2021 | |
| Pfizer INC. | $117.28 | 2019 | |
| Glaxosmithkline, LLC. | $99.63 | 2019-2021 | |
| Amarin Pharma, INC. | $77.24 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $41.54 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.11 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.48 | 2021 | |
| Astellas Pharma US INC | $25.84 | 2019-2021 | |
| Abbvie INC. | $23.47 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.51 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.08 | 2019 | |
| Lilly USA, LLC | $16.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.29 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Montesi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.